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ARTICLE
Life-Course Genome-wide Association Study
Meta-analysis of Total Body BMD
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Bone mineral density (BMD) assessed by DXA is used to evaluate bone health. In children, total body (TB) measurements are commonly
used; in older individuals, BMD at the lumbar spine (LS) and femoral neck (FN) is used to diagnose osteoporosis. To date, genetic variants
in more than 60 loci have been identified as associated with BMD. To investigate the genetic determinants of TB-BMD variation along
the life course and test for age-specific effects, we performed a meta-analysis of 30 genome-wide association studies (GWASs) of TB-BMD
including 66,628 individuals overall and divided across five age strata, each spanning 15 years. We identified variants associated with
TB-BMD at 80 loci, of which 36 have not been previously identified; overall, they explain approximately 10% of the TB-BMD variance
when combining all age groups and influence the risk of fracture. Pathway and enrichment analysis of the association signals showed
clustering within gene sets implicated in the regulation of cell growth and SMAD proteins, overexpressed in the musculoskeletal system,
and enriched in enhancer and promoter regions. These findings reveal TB-BMD as a relevant trait for genetic studies of osteoporosis,
enabling the identification of variants and pathways influencing different bone compartments. Only variants in ESR1 and close
proximity to RANKL showed a clear effect dependency on age. This most likely indicates that the majority of genetic variants identified
influence BMD early in life and that their effect can be captured throughout the life course.Introduction
Osteoporosis is a disease characterized by low bone mass
andmicroarchitectural deterioration of bone tissue leading
to increased risk of fracture.1 It is diagnosed through
the measurement of bone mineral density (BMD) utilizing
dual-energy X-ray absorptiometry (DXA), which is the
single best predictor of fracture.1
Bone is a dynamic tissue constantly undergoing resorp-
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 2017 American Society of Human Genetics.childhood and markedly during adolescent growth.2 Peak
bone mass is attained at approximately the third decade
of life. Thereafter, until about 50 years of age, BMD remains
fairly stable, by virtue of the coupling between bone forma-
tion and resorption (e.g., bone remodeling). Subsequently,
bone resorption exceeds the rate of bone formation, result-
ing in a decrease in BMD, particularly in women after the
onset of menopause.3
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of BMD determinants are frequently based on measure-
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of bone health in children and adolescents, total body
(excluding head) and lumbar spine are the preferred sites
to minimize measurement artifacts resulting from chang-
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less, in elderly individuals degenerative changes in the
spine can give elevated BMD readings.4 Moreover, total
bodyDXAscanshave beenobtained inmanyadult research
cohorts, primarily to assess body composition. Therefore,
the total body BMD (TB-BMD) measurement is the most
appropriate method for an unbiased assessment of BMD
variation in the same skeletal site fromchildhood toold age.
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The Amebone parameters.5–17 Most of these markers have been
identified in studies comprising tens of thousands of adult
and elderly individuals with DXA-derived BMD measure-
ments, although a few of them have been associated
with BMD specifically in studies of pediatric cohorts.7
Furthermore, several of the associated variants display sig-
nificant site-specific effects, possibly reflecting differences
in bone composition across skeletal sites (e.g., cortical
bone versus trabecular bone) or differential response to
mechanical loading.7 Moreover, genetic studies on mea-
sures from peripheral quantitative computed tomography
(pQCT) and bone quantitative ultrasound, which provide
additional information regarding bone size, geometry,
and (micro) architecture, identified genetic variants that
may have specific effects on bone properties that are
poorly captured by conventional DXA measurements.8,9
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possible that genetic studies in more refined age groups
will reveal variants in unreported loci as well as age-specific
genetic effects. Thus, the purpose of this study was to
identify gene variants associated with TB-BMD across the
lifespan and to investigate possible differences of genetic
effects across age periods.Subjects and Methods
TB-BMD GWAS Meta-analyses
Subjects, BMD Measurement, and Imputation
This study comprised 30 epidemiological studies
comprising 66,628 individuals from populations across
America, Europe, and Australia, with a variety of designs
(Supplemental Data; Table S1) and participant character-
istics (Table S2). In summary, most participants came
from population-based cohorts of European ancestry
(86%), two cohorts comprised African American individ-
uals (2%), and four other studies held a fraction of indi-
viduals from admixed background (14%). All research
aims and the specific measurements have been approved
by the correspondent Medical Ethical Committee of
each participating study. Written informed consent was
provided by all subjects or by their parents in the case
of children.
Total body BMD (g/cm2) was measured by DXA
following standard manufacturer protocols. As recommen-
ded by the International Society for Clinical Densitometry,
total body less head (TBLH) was the measurement used in
pediatric cohorts (see Web Resources) (e.g., 0–15 years).
Detailed information on the assessments performed by
each study can be found in Table S1.
All individuals included in this study had genome-wide
array data. Quality control of genotypes is summarized in
Table S1. To enable meta-analysis, each study performed
genotype imputation using the cosmopolitan (all ethnic-
ities combined) 1000 Genomes phase 1 v.3 (March 2012)
reference panel, yielding 30,000,000 SNPs for analysis.
Three studies used the combined 1000 Genomes and the
UK10K reference panels as presented in Table S1.
Association Analysis, Quality Control, and Assessment
TB(LH)-BMD was corrected for age, weight, height, and
genomic principal components (derived from GWAS
data), as well as any additional study-specific covariates
(e.g., recruiting center), in a linear regression model. For
studies with non-related individuals, residuals were
computed separately by sex, whereas for family-based
studies sex was included as a covariate in the model.
Finally, residuals were inverse normal transformed. The
analyses were performed in each study for the overall
population as well as in subgroups of individuals by age
strata, defined by bins of 15 years (i.e., 0–15 years, 15–30
years, 30–45 years, 45–60 years, and 60 or more years).
SNP association was tested for autosomal variants, in
which the additive effect of each SNP on the normalized
BMD residuals was estimated via linear regression.90 The American Journal of Human Genetics 102, 88–102, January 4,A centralized quality-control procedure implemented in
EasyQC18 was applied to all study-specific files of associa-
tion results to identify cohort-specific issues. We excluded
variants if they had missing information (e.g., missing
association p value, beta estimate, alleles, allele frequency),
nonsensical values (e.g., absolute beta estimates or
standard errors> 10, association p values> 1 or< 0, impu-
tation quality < 0, infinite beta estimates or standard
errors), minor allele frequency (MAF) less than 0.5%, or
imputation quality scores < 0.4 (Impute2) or < 0.3
(Minimac).Moreover, variantswereflagged if theyhad large
allele frequency deviations from reference populations
(>0.6 for admixed studies and >0.3 for ancestry-homoge-
neous studies).
In the first instance, no exclusion criteria based on
ancestry were applied for the meta-analysis (N ¼ 66,628).
In addition, meta-analyses were carried out across age
strata (minimum sample size per bin N ¼ 200 for each
study) comprising 0–15 years (N ¼ 11,807), 15–30 years
(N ¼ 4,180), 30–45 years (N ¼ 10,062), 45–60 years
(N ¼ 18,805), and 60 or more years (N ¼ 22,504). Further,
summary data from cohorts of European ancestry only
were meta-analyzed and used in subsequent analyses.
We discarded variants present in fewer than three
studies. Approximately 23,700,000 markers (including
SNPs and INDELS) were assessed for association. We
applied the conventional genome-wide significance level
(GWS, p < 5 3 108) for SNP discovery.
We selected SNPs that were suggestively (12,567 SNPs,
p < 5 3 106) associated with BMD in the overall meta-
analysis, present in at least two studies per age bin, and
with MAF differences across these meta-analyses lower
than 0.5. We clumped this dataset with an r2R 0.8, using
as reference the most strongly associated SNPs with BMD
and pruning remaining SNPs within 0.7 Mb of each other.
Age-dependent effects were assessed using a meta-regres-
sion approach for 1,464 SNPs obtained after this selection
procedure. We ran a linear regression of the SNP effect
estimates onto an intercept and the median age of each
subgroup (e.g., each study stratified in age bins). As pro-
posed previously,19 standard errors of the effect estimates
of each subgroup were multiplied by the square root of
the genomic inflation factor when it was greater than 1.
We performed the meta-regression using the Metafor pack-
age,20 and any statistical evidence of linear association was
corrected for multiple testing (Bonferroni correction; 0.05/
1,464 ¼ 3.4 3 105). The difference between beta-esti-
mates in children versus elderly meta-analyses (Pdiff) was
tested using Easy-strata.21
Conditional analyses were undertaken based on the
meta-analysis of the studies of European ancestry only
(N ¼ 56,284). Only variants in the loci that reached
GWS in this meta-analysis were assessed. The Rotterdam
Study I (n ¼ 6,291) was used as reference for precise calcu-
lation of the linkage disequilibrium (LD) between the
analyzed markers. We used an iterative strategy as imple-
mented in GCTA22 to determine (1) independence of2018
association signals within loci discovered in our study,
by means of stepwise model selection procedure per chro-
mosome (–massoc-slct routine) and (2) the novelty of the
association signals discovered by our meta-analysis with
regard to variants reported in previous well-powered
GWASs of different bone traits (Table S3). To this end, we
performed the association analysis conditional on 78 vari-
ants present in our data and associated with different bone
traits (–massoc-cond routine). These 78 SNPs were selected
from different GWAS publications,5–9,11–13 assuring their
independence to avoid collinearity issues.
Shared Genetic Architecture of TB-BMD Fracture and
Other Traits
LD Score Regression Analyses
We used the LD score regression package to estimate the
heritability of TB-BMD and to rule out that our results
were a product of bias (e.g., residual population stratifica-
tion or cryptic relatedness). LD score regression uses
GWAS summary statistics and assesses the SNP heritability
based on the expected relationship between LD of neigh-
boring SNPs and strength of association under a polygenic
model.23 As this methodology relies on the LD structure
throughout the genome, we restricted this analysis to sum-
mary statistics from the meta-analysis of cohorts
comprising only individuals from European ancestry. We
used the publicly available, pre-computed LD structure
data files specific to European populations of the HAPMAP
3 reference panel. An extension of this method allows
estimating the genetic correlation between two traits.24
This can be performed in the LDhub pipeline, a web
utility that gathers data from many different GWAS
meta-analysis.25 From the 199 traits, currently available
in the website, we have restricted our analysis to those
traits whose heritability z-scores were larger than 4 and
were analyzed only in European ancestry individuals
(following the recommendations in the LD score software
website [Web Resources]). Additionally, we incorporated
data from a recent GWAS meta-analysis of any type of frac-
ture in individuals from European ancestry (N ¼ 264,267;
37,778 case subjects) (K.T., unpublished data). In total,
we assessed the genetic correlation between TB-BMD and
74 traits.
Mendelian Randomization Analysis
We undertook a two-sample Mendelian randomization
approach26 to estimate the causal effect of TB-BMD on
any type of fracture in the Europeans samples. In short,
we constructed a score based on the independent genetic
variants from the TB-BMD meta-analysis (European set
and excluding secondary signals); whenever the selected
variant was not present in the fracture meta-analysis,
the second variant with the lowest p value in the locus
(p < 5 3 108) and r2 > 0.8 was used as proxy. Thereafter,
estimates derived from the TB-BMD summary statistics
were pooled using methods similar to inverse-variance
weighted fixed meta-analysis using the meta R-package
(Web Resources).The AmeSearch for Biological and Functional Knowledge of the
Identified Association Regions
For all those SNPs outside a 500 kb window from previ-
ously known bone-associated SNPs, we did a literature
search in PubMed and Web of Science to evaluate whether
nearby genes (within 500 kb) were known to play a role in
bone metabolism. Also, we determined whether the anno-
tated genes underlie any humanMendelian disorder with a
skeletal manifestation, had knockout mouse models with a
skeletal phenotype, or were annotated to pathways critical
to bone metabolism. Genomic annotation for all SNPs was
made based on UCSC hg19.
DEPICT Analyses
We used DEPICT,27 a recently developed tool to prioritize
genes at the associated regions, define possible pathways
by enrichment testing, and identify tissue and cell types
in which genes from loci associated with TB-BMD. The
methodology first selects all lead SNPs below a certain
threshold with respect to a target p value. We tested both
the complete set of GWS SNPs and the subset of thosemap-
ping only to loci not previously reported. Enriched gene
sets were group based on the degree of gene overlap into
‘‘meta gene-sets’’ as proposed earlier,28 and their correla-
tion visualized using Cytoscape 3.4 (Web Resources).
Functional Annotation to MicroRNA Binding Sites
We used the PolymiRTS,28 miRdSNP,29 and microSNiPer30
databases to obtain a list of variants located in predicted
microRNA binding sites on the 30 UTRs of genes, as
described in detail elsewhere.31 In summary, index SNPs
(most associated variants) of the GWS loci were submitted
to SNAP (Web Resources) to retrieve their high LD proxy
SNPs (with r2 > 0.8, limit distance 500 kb, and CEU panel)
in the 1000Genomes project. The resulting list of SNPs was
annotated to the list of microRNA binding site variants
obtained from the above mentioned publicly available
databases.
Functional Enrichment Analysis of Trait-Associated Variants
GWAS analysis of regulatory or functional information
enrichment with LD correction (GARFIELD)32 was used
to characterize the putative functional contribution of
TB-BMD-associated variants mapping to non-coding re-
gions. GARFIELD employs a non-parametric analysis to
calculate fold enrichment values for regulatory marks, at
given significance thresholds, and then tests them for sig-
nificance via permutation testing while accounting for LD,
MAF, and local gene density.32 We used data regarding
DNase-I hypersensitive sites, transcription factor bind-
ing sites, histone modifications, and chromatin states
(ENCODE and Roadmap Epigenomics) from 424 cell
types and tissues to capture and characterize possible
cell-type-specific patterns of enrichment, as provided in
the GARFIELD software (Web Resources). Fold enrichment
statistics were tested at the four different significance
thresholds (i.e., 1 3 108, 1 3 107, 1 3 106, and
1 3 105). Multiple-testing correction was performed
on the effective number of annotations used, using the
default p value threshold of 1 3 104.rican Journal of Human Genetics 102, 88–102, January 4, 2018 91
Figure 1. Manhattan Plot of Association
Statistics (log10(p Values)) for TB-BMD
Overall Meta-analysis
Each dot represents a SNP and the x axis
indicates its chromosomal position (built
37 NCBI). Red dots represent SNPs at
GWS loci that are not within 5500 kb of
leading SNPs in previous GWASs with
different bone traits. Dashed horizontal
red and yellow lines mark the GWS
threshold (p < 5 3 108) and suggestive
threshold (p < 1 3 106), respectively.
Novel loci in the only-CEU analysis are
not shown.Knockout Animal Models and Gene Expression in Bone
Cells
Animal Models Survey
We surveyed databases from The International Mouse Phe-
notyping Consortium33 together with The International
Knockout Mouse Consortium34 to identify knockout
models of candidate genes resulting in skeletal pheno-
types. Furthermore, we mined data from The Origins of
Bone and Cartilage Disease (OBCD) project,35 specialized
in murine skeletal phenotypes including digital X-ray
microradiography on femurs and tail vertebrae, micro-CT
analysis, femur three-point bend test load-displacement
curves, and tail vertebrae compression testing from
knockout mice and wild-type controls at 16 weeks of age.
Experiments were undertaken by the Wellcome Trust
Sanger Institute Mouse Genetics Project as part of the
IKMC and licensed by the UK Home Office in accordance
with the Animals (Scientific Procedures) Act 1986 and
the recommendations of the Weatherall report.
Gene Expression in Bone Cells
Gene expression profiles of candidate genes were exam-
ined in primary mouse osteoblasts undergoing differentia-
tion and bone marrow-derived osteoclasts. To study mu-
rine osteoblasts, pre-osteoblast-like cells were obtained
fromneonatal calvaria collected fromC57BL/6J. Next Gen-
eration RNA sequencing using an Illumina HiSeq 2000 was
used to evaluate the transcriptome every 2 days from day 2
to 18 days after osteoblast differentiation.6 Expression of
genes in murine osteoclasts was determined using publicly
available data obtained using Next-Gen RNA-sequencing
applied to bone marrow-derived osteoclasts obtained
from 6- to 8-week-old C57BL/6 mice.36 All procedures
and use of mice for the neonatal osteoblast expression
studies were approved by the Jackson Laboratory Animal
Care and Use Committee (ACUC), in accordance
with NIH guidelines for the care and use of laboratory
animals.
Gene expression profiles of candidate genes were exam-
ined in human bone marrow-derived mesenchymal stem
cells differentiated into osteoblast. Total RNA (n ¼ 3) was
isolated at day 0 (MSCs) and day 4 of osteoblast differentia-
tion.37 Also, RNAwas isolated during osteoclast differentia-
tion. Peripheral blood mononuclear cells derived from92 The American Journal of Human Genetics 102, 88–102, January 4,buffy coats (Sanquin) were seeded in 96-well plates
(5 3 105 cells per well) as previously described.38 Total
RNA (n ¼ 3) was isolated using Trizol at day 0 (PBMCs)
and at day 7 of osteoclast differentiation. Illumina Hu-
manHT-12 v3 BeadChip human whole-genome expression
arrays were used for expression profiling. The quality of iso-
latedRNAwas assessedona2100Bioanalyzer (AgilentTech-
nologies). Data were analyzed as described in detail previ-
ously.37 Genes were designated as being expressed when
at least one probe coding for the gene was significantly pre-
sent in at least two of the three biological replicates.Results
TB-BMD GWAS Meta-analyses
Analyses Including All Age Strata
Our meta-analysis of TB-BMD GWAS summary statistics
(N ¼ 66,628) identified variants in 76 independent loci
associated with TB-BMD at a genome-wide significant
(GWS, p % 5 3 108) level (Figure 1, Table S4). Overall,
there was no evidence of a strong inflation (genomic infla-
tion factor [l] of 1.08, Figure S1). Yet, inflation was
observed in the range of common variants (0.2 > MAF <
0.5, l ¼ 1.19) due to polygenicity (LD score regression
intercept ¼ 1.007). In our results, one of the signals map-
ping to LDLRAD3 was driven entirely by individuals of
African background (MAF ¼ 0.043 in YRI panel) since the
two associated variants are monomorphic in all other
populations. The low allele frequency of this variant in
our study (MAF ¼ 0.025) and our limited statistical power
(N ¼ 6,748) in non-European samples warrants indepen-
dent replication efforts to exclude the possibility of a
false-positive association.
In addition, a meta-analysis comprising 56,284 individ-
uals of European ancestry (84% of the study population)
identified variants in two additional GWS loci (Figures S1
and S2, Table S5). Association signals mapping to these
loci were close to the GWS threshold in the overall meta-
analysis (p ¼ 13 107) and showed no evidence of hetero-
geneity (phet > 0.1). One of them, in 12q24.21 (MED13L),
has not been previously associated with bone parameters
(Table 1, Figure S3), while the other in 21q22.132018
Table 1. Index SNPs of Loci Not Previously Associated with BMD
CHR BP rs Number Locus A1 A2 EAF Effect p N Annotation Closest Gene Notes LS-beta LS-P FN-beta FN-P
1 8422676 rs2252865 1p36.23 T C 0.32 0.033 4.72 3 108 66,075 intronic RERE novel biology 0.019 0.043 0.025 0.002
1 110475971 rs7548588 1p13.3 T C 0.61 0.037 9.29 3 108 66,240 intergenic CSF1 osteoclast differentiation39 0.030 0.001 0.022 0.005
1 220038825 rs185048405 1q41 T C 0.54 0.042 3.07 3 108 66,540 intronic SLC30A10 manganese transport40 0.035 0.076 0.003 0.878
2 27741072 rs780096 2p23.3 C G 0.44 0.031 4.58 3 108 66,578 intronic GCKR calcium regulation,41
hepatic traits42
0.014 0.129 0.017 0.029
2 40630678 rs10490046 2p22.1 A C 0.76 0.043 1.43 3 1010 65,961 intronic SLC8A1 bone mineralization43 0.015 0.162 0.021 0.025
2 68962137 rs10048745 2p13.3 A G 0.25 0.039 6.44 3 108 66,565 50 UTR ARHGAP25 novel biology 0.050 1.03 3 106 0.036 5.21 3 105
2 85484818 rs11904127 2p11.2 A G 0.55 0.032 2.65 3 108 66,561 intronic TCF7L1 factors in Wnt signaling44 0.021 0.023 0.015 0.054
2 198874006 rs1595824 2q33.1 T C 0.47 0.034 2.65 3 108 60,171 intronic PLCL1 negative regulation of bone
formation45
0.022 0.201 0.052 2.20 3 104
2 202799604 rs2350085 2q33.2 T C 0.87 0.064 3.80 3 1014 66,412 intergenic FZD7 factors in Wnt signaling46 0.042 0.002 0.044 1.96 3 104
2 234303405 rs838721 2q37.1 A G 0.44 0.031 4.48 3 108 65,516 intronic DGKD calcium regulation41 0.016 0.070 0.014 0.068
5 112221869 rs818427 5q22.2 T C 0.31 0.034 2.37 3 108 66,592 intronic APC bone metabolism47 0.004 0.645 0.008 0.327
5 122847622 rs11745493 5q23.2 A G 0.75 0.044 7.75 3 1012 66,597 promoter CSNK1G3 novel biology 0.010 0.326 0.025 0.005
7 27989403 rs757138 7p15.1 T G 0.69 0.035 3.33 3 108 66,043 intronic JAZF1 novel biology 0.016 0.126 0.025 0.004
7 30957702 rs28362721 7p14.3 T C 0.18 0.059 6.71 3 1014 66,274 intronic AQP1 bone metabolism48 0.037 0.002 0.049 1.39 3 106
7 50901491 rs1548607 7p12.1 A G 0.69 0.036 4.18 3 108 66,564 intergenic GRB10 novel biology 0.034 5.59 3 104 0.005 0.517
7 99130834 rs34670419 7q22.1 T G 0.04 0.088 1.09 3 108 66,336 30 UTR ZKSCAN5 DHEAS and aging mechanisms49 0.127 9.28 3 108 0.080 8.19 3 105
10 112245400 rs73349318 10q25.2 A T 0.87 0.047 2.68 3 108 66,341 intronic DUSP5 osteoclast differentiation50 0.042 0.001 0.051 8.76 3 106
10 124015986 rs10788264 10q26.13 A G 0.48 0.034 2.61 3 108 66,565 intergenic TACC2 novel biology 0.030 9.64 3 104 0.029 1.29 3 104
11 242859 rs55781332 11p15.5 A G 0.78 0.055 8.07 3 1016 66,198 intronic PSMD13 novel biology 0.046 1.76 3 105 0.026 0.005
11 35083633 rs2553773 11p13 C G 0.41 0.037 1.49 3 1010 66,619 intergenic CD44 osteoclast activity51 0.015 0.101 0.015 0.054
11 35981346 rs113964474a 11p.13* A G 0.03 0.485 1.41 3 108 6,748 intronic LDLRAD3 novel biology – – – –
11 69299537 rs4980659 11q13.3 C G 0.52 0.033 1.16 3 108 66,537 intergenic CCND1 target of Wnt signaling52 0.039 1.58 3 105 0.023 0.003
11 121913230 rs725670 11q24.1 A G 0.38 0.032 3.61 3 108 66,565 intergenic BLID novel biology 0.020 0.028 0.011 0.172
12 90334829 rs10777212 12q21.33 T G 0.35 0.045 5.05 3 1014 66,619 intergenic ATP2B1 calcium absorption53 0.028 0.003 0.021 0.010
12 116555786 rs73200209b 12q24.21 A T 0.80 0.045 2.51 3 108 51,240 intronic MED13L novel biology 0.030 0.167 0.036 0.044
13 37487021 rs556429 13q13.3 A C 0.23 0.039 1.46 3 108 66,504 intronic SMAD9 osteoblast differentiation54 0.023 0.027 0.013 0.135
15 38340874 rs12442242 15q14 A G 0.85 0.051 4.94 3 1010 66,403 intergenic TMCO5A novel biology 0.046 3.03 3 104 0.047 2.26 3 105
15 51537806 rs2414098 15q21.2 T C 0.39 0.033 1.99 3 108 66,562 intronic CYP19A1 estrogen byosynthesis55 0.034 0.007 0.038 0.001
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94 The American Journal of Human Genetics 102, 88–102, January 4,(CLDN14) is not fully independent from the previously re-
ported hip BMD association signal12 (Table S5).
Of the 78 identified loci, variants in 35 (45%) were not
located within 500 kb of known association signals nor
in regions of extended LD with them (Table 1, Figure S4).
Index SNPs at these 35 loci were, in general, common
non-coding variants. Twenty-two of these are located in
close proximity to genes likely to influence bone meta-
bolism as shown by previous functional studies (Table 1,
Figure S3), including CSF1 (MIM: 120420), important for
osteoclast differentiation,39 and SMAD3 (MIM: 603109), a
critical component of the TGF-b signaling pathway.56
Across these 35 signals, 31 of the index SNPs were nomi-
nally associated (p < 0.05) with either lumbar spine or
femoral neck BMD in the same direction as in the previ-
ously published GEFOS GWAS meta-analysis6 (Table 1).
This comparison was not possible for the rs113964474
variant, because it was not available in the GEFOS study.
Moreover, we found directionally concordant effect esti-
mates (p < 0.05) for 73 of the 78 index SNPs of known
bone association signals (Table S3). The markers that failed
to replicate in our study were either previously associated
with lumbar spine BMD but not femoral neck BMD
(rs3905706 [MPP7, 10p12.1] and rs1878526 [INSIG2,
2q14.2]), associated specifically with the hip trochanter
and intertrochanteric sub-regions (rs1949542 [RP11-
384F7.1, 3q13.32]), or associated with BMD only in
women (rs7017914 [XKR9, 8q13.3]) or only in children
(rs754388 [RIN3, 14q32.12]).
Age-Dependent Effects
Meta-analyses across age strata resulted in the identifica-
tion of variants mapping to two additional loci that were
not detected in the overall meta-analysis (Figure S5; Table
S6). In children (age group 0–15 years), the previously
known 14q32.12 locus,7 harboring RIN3 (rs72699866,
p ¼ 1 3 108), and in the middle-aged (age group 45–60
years), a signal in the 19q12 locus mapping in the vicinity
of TSHZ3 (rs6510186, p ¼ 3.1 3 108) were identified.
The rs72699866 variant leading the RIN3 signal in the
youngest age stratum showed no evidence of association
(p ¼ 0.16) and high heterogeneity (phet ¼ 6.6 3 105)
in the overall meta-analysis. In fact, the effect of
rs72699866 decreased significantly with age (ptrend ¼
1.69 3 109) (Figure S6) and showed a significant
difference between the two extreme groups, i.e., children
versus elderly (b0-15 ¼ 0.099 [0.066, 0.134]; b>60 ¼
0.035 [0.060,0.010]; pdiff¼ 4.323 1010). In contrast,
the rs6510186 variant (19q12) showed nominal evidence
of association and heterogeneity in the overall meta-anal-
ysis (p ¼ 0.02; phet ¼ 0.03). Nevertheless, no clear pattern
of age dependency was identified (p ¼ 0.2) for this SNP
(Figure S6).
We also applied meta-regression analysis and found
that variants mapping to 42 different loci showed nomi-
nally significant age-dependent effect (p < 0.05) (Table
S7; Figure S7). In summary, 27 (64%) of the loci showed
stronger effects in the older age groups. Of these,2018
Figure 2. Age Dependence of the Genetic Variant Effect in the Meta-regression
The panels display leading SNPs from two loci exhibiting significant evidence for age influences. Heterogeneity p values (phet) are
reported for the overall meta-analysis. In the left panels, each circle represents a study subgroup (i.e., study divided in age strata),
with the circle size proportional to the inverse variance of the SNPmain effect. In the right panels, forest plots display estimates obtained
from each age-bin meta-analysis, with the symbol size proportional to the inverse variance of the SNP main effect.variants in the 6q25.1 (ESR1) and 13q14.11 (RANKL) loci
remained significant after multiple-testing correction
(p < 3.4 3 105) (Figure 2), while variants in 6p21.1
(RUNX2, rs148460475), 15q21.2 (CYP19A1, rs2414098),
17q21.31 (MEOX1, rs74835612), and 11p15.1 (SOX6,
rs11822790) were only suggestive at p < 1 3 103.
Conditional Association Analyses
The stepwise conditional approach included studies
comprising only individuals of European ancestry, as the
method used relies on appropriate representability of the
LD reference. Of the 76 GWS loci identified in the overall
analysis, variants in 57 (19 previously unreported) loci
were also GWS in the European-only analysis (Figure S2),
likely a consequence of the lower power in this subgroup.
We identified 81 SNPs independently associated with
TB-BMD mapping to 58 different loci (one European-spe-
cific), 18 of which depicted multiple distinct signals attain-
ing GWS (Table S8). These independent variants together
explained 10.2% of TB-BMD variance. This proportion is
slightly higher than the 7.4% TB-BMD variance explained
by the 78 known variants associated with bone traits.
Moreover, we identified independent signals in 13 of the
78 known bone loci after conditional analyses (Figure S2;
Table S8).The AmeShared Genetic Architecture of TB-BMD, Fracture,
and Other Traits
SNP heritability of TB-BMD in the European samples
was estimated to be 0.259 (SE 0.017). TB-BMD was highly
genetically correlated with BMDmeasured at other skeletal
sites (r > 0.9). Among the non-BMD traits, all types
of fracture showed the highest correlation (r ¼ 0.61
[p ¼ 1.6 3 1027]). The MR approach indicated a strong
causal relation where, per 1 standard deviation decrease
in genetically determined TB-BMD, there is 56% increase
in the risk of fracture (odds ratio 1.56 [1.50–1.62]). Other
anthropometric, metabolic, and disease traits showed sig-
nificant (yet weak) correlation with TB-BMD (Table S9,
Figure 3). In contrast, other established risk factors for oste-
oporosis such as menopause or age of menarche showed
no significant genetic correlation with TB-BMD.
Biological and Functional Knowledge of the Genes in
BMD-Associated Loci
Locinotpreviously reportedand their potential role inbone
metabolism are summarized in Table 1. Several loci harbor
genes implicated directly in bone metabolism (SLC8A1
[MIM: 182305], PLCL1 [MIM: 600597], ADAMTS5 [MIM:
605007]), affecting osteoblast or osteoclast differentiationrican Journal of Human Genetics 102, 88–102, January 4, 2018 95
Figure 3. Genetic Correlations between TB-BMD and Other Traits and Diseases
Calculation was based on the summary statistics of the only-European meta-analysis (N ¼ 56,284) and estimated by LD score regression
implemented in LDHub. The diagram shows only traits whose correlation with TB-BMD was significant (p < 0.05).and activity (CSF1 [MIM: 120420], DUSP5 [MIM: 603069],
SMAD3 [MIM: 603109], SMAD9 [MIM: 603295], CD44
[MIM: 107269]), participating in Wnt signaling (FZD7
[MIM: 603410], TCF7L1 [MIM: 604652]), or regulating pro-
cesses such as manganese or calcium absorption (GCKR
[MIM: 600842], DGKD [MIM: 601826], SLC30A10 [MIM:
611146]) among others;39–60 while genes in at least 14 loci
exert a potential novel role in bone biology. Rodent
knockout models of several genes in the implicated
loci show an altered skeletal phenotype (e.g., ostoepetrosis
[Csf139], increased bone resorption [Aqp1,48 Cyp19a1,55
Cd4451], impaired skeletogenesis [Apc,47Runx1,59 Smad356],
deformities in the axial skeleton [Btg1,61 Atpaf262]). An ef-
fect on bone can be inferred for genes in other associated
loci, for example, CYP19A1 (MIM: 107910) in 15q21.2 is
an estrogen synthesis gene, estrogenbeing a key compound
for bone maturation and maintenance, and ZKSCAN5
(MIM: 611272) in 7q22.1 is associated with circulating
dehydroepiandrosterone sulfate (DHEAS) levels.49 DHEAS
levels are positively correlated with BMD in adults and
post-menopausal women.63 Across these loci, not previ-
ously reported as associated with BMD variation, we iden-
tified six exonic variants associated with TB-BMD, three
of which were nonsynonymous variants all cataloged
as benign both by SIFT and PolyPhen-2. We also iden-
tified 53 GWS coding variants in known loci, of96 The American Journal of Human Genetics 102, 88–102, January 4,which 33 are non-synonymous (Table S10). Only a low-
frequency variant in LRP5 (MIM: 603506), rs4988321/A
(11:68174189, MAF ¼ 0.04), has a clinical annotation,
constituting a homozygous G-to-A transition variant
identified in a person with osteoporosis-pseudoglioma
syndrome (OPPG [MIM: 259770]).64
DEPICT Analyses
Based on the overall meta-analysis, 53 genes were priori-
tized (FDR < 0.05), 15 of them mapping to loci not previ-
ously described (Table S11). Cells and tissues from the
musculoskeletal system presented the largest enrichment
of gene expression within the associated loci (Figure 4).
These genes were overrepresented in 182 pathways clus-
tered in 25 ‘‘meta gene-sets’’ (Table S12). The large majority
of the clusters are involved in musculoskeletal develop-
ment and bone homeostasis (Figure 4). The most signifi-
cant of these implicated the regulation of cell growth
and the TGFB signaling pathway and its mediating
SMAD proteins.
Restricting the DEPICT analysis to the subset of not pre-
viously reported associated regions resulted in significant
enrichment of genes expressed in the musculoskeletal
and immunological systems (Figure S8). Genes mapping
to these loci were overrepresented in the SMAD binding
pathway and TGFBR2 PPI (protein-protein interaction)
subnetwork (FDR < 0.05).2018
Figure 4. Results for Gene Set and Cell/Tissue Enrichment Analyses
Top: 25 Meta gene sets were defined from similarity clustering of significantly enriched gene sets (FDR < 5%). Each meta gene set
was named after one of its member gene sets. The color of the meta gene sets represents the p value of the member set. Interconnec-
tion line width represents the Pearson correlation r between the gene membership scores for each meta gene set (r < 0.3, no line;
0.3 % r < 0.5, narrow width; 0.5 % r < 0.7, medium width; r R 0.7, thick width). Bottom: Bars represent the level of evidence
for genes in the associated loci to be expressed in any of the 209 medical subject heading (MeSH) tissue and cell type annotations.
Highlighted in orange are these cell/tissue types significantly (FDR < 5%) enriched for the expression of the genes in the associated
loci.Functional Annotation to MicroRNA Binding Sites
We then assessed whether the index SNPs of the 80 GWS
loci detected in the main and subsequent GWAS (or their
proxies in strong LD; r2> 0.8) were located in predictedmi-
croRNA binding sites within the genes’ 30 UTRs and thus
were expected to disrupt the regulation of gene expression
(Table S13). The index SNP within the 30 UTR of ZKSCAN5
(mapping to a locus not previously identified), rs34670419
(MAF ¼ 0.04), is predicted to create a binding site for miR-
382-3p, a microRNA that is expressed in osteocytes and
has been recently shown to be involved in osteogenic
differentiation.65 In addition, eight proxy SNPs (mapping
to PSMD13, ABCF2, GALNT3, PKDCC, REEP5, PPP6R3,
AAGAB, and TOM1L2) are predicted to influence the bind-
ing of microRNAs to transcripts of their host gene.
Functional Enrichment Analysis of Trait-Associated Variants
As typically found in GWASs, the great majority of identi-
fied associations emerged from non-coding common vari-
ants and hold no direct annotation to molecular mecha-
nisms. To assess whether there is relative enrichment of
regulatory genomic marks underlying the associated vari-The Ameants in a cell-specific context, we used GARFIELD.32 We
found relative ubiquitous enrichment for TB-BMD variants
(empirical p < 2.4 3 104) in DNase I hypersensitive sites
across the different cell types (Figure S9). Further, we found
higher levels of fold-enrichment for enhancers (median
3.6, range [2.7, 4.4]) and promotors (median 3.2, range
[2.9, 3.5]) than for transcribed regions (median 1.8, range
[1.5, 2.2]).
Gene Expression in Bone Cells and Knockout Animal Models
From the 53 genes prioritized by DEPICT, only 49 had
a mouse ortholog (Table S14). From these genes, only
Mepe (osteocyte-specific) and Foxl1 were not expressed
in murine osteoblast or osteoclast. Moreover, 61% of
the prioritized genes were expressed in human cells
in vitro during osteoblast or osteoclast differentiation
(Table S14). AQP1 was the only prioritized gene map-
ping to a locus not previously reported showing no
expression in the human bone cells differentiation
experiments.
Knockout models were widely available in at least one
of the different databases assessed. Nevertheless, in-depthrican Journal of Human Genetics 102, 88–102, January 4, 2018 97
bone phenotyping performed under the OBCD project
was available for only four knockout models (Table S15).
Two of these, DUSP5 and CD300LG, showed no signifi-
cant bone phenotype. The TCF7L1 knockout model
only showed lower cortical diameter in the femur
without other clear bone phenotype. Nevertheless,
TCF7L1 was shown to be expressed during osteoblasto-
genesis. Conversely, homozygous knockout for CREB3L1
showed a clear bone phenotype consisting of low BMC
both at the vertebrae and femur together with a strong
trabecular and cortical phenotype affecting bone strength
(Figure S10). CREB3L1 maps to 11p11.2, a previously
identified BMD locus5 harboring ARHGAP1 and LRP4
as candidates to underlie the GWAS signal in a region of
extended LD.Discussion
This meta-analysis of TB-BMD comprising up to 66,000
individuals identified variants in 36 loci not previously re-
ported and replicated at GWS level several association sig-
nals identified by GWASs of diverse bone phenotypes. Bio-
informatics analyses suggest enrichment of these 36 loci
for genes expressed in the musculoskeletal system and sol-
idly represented in the SMAD binding pathway and the
TGFBR2 PPI subnetwork. We also demonstrate that for var-
iants in few loci the size of the effect is age dependent; var-
iants in two loci (RIN3 and TSHZ3) were identified only by
the age-stratified analyses despite less power (smaller sam-
ple size); while for variants in two other loci (ESR1 and
RANKL) there was significant evidence of age heterogene-
ity derived from a meta-regression of the genetic effects
with age. Our results strengthen the evidence that genetic
variants influence BMD from a young age and support the
value of peak bone mass as an important determinant of
bone health later in life.
Traditionally,DXA-BMDmeasurementsperformedat sites
of high fracture risk (i.e., femoral neck, lumbar spine and
forearm) have been used in genetic epidemiological investi-
gations of bonehealth in adults. Instead, wehave used BMD
measurements derived from total body scans. Not only do
we show a high overlap of association signals with previous
GWASs of different bone traits, including DXA, pQCT, and
ultrasoundmeasurements, but we have also identified unre-
ported loci. Five knownassociations failed to replicate in our
studies, even thoughwe cannot discard these associations as
false positives, because these results might also indicate that
variants whose effect is highly specific to skeletal sites, skel-
etal properties, sex, or age groups cannot be detected in
our TB-BMDmeta-analysis. It is plausible thatmore variants
of this type exist and will be discovered as site-specific BMD
meta-analyses are performed in increasingly powered set-
tings. Furthermore, the genetic correlation of TB-BMD
with BMD measured at other sites was close to one. Never-
theless, we found that a decrease of one standard deviation
in the genetically determined TB-BMD resulted in at least98 The American Journal of Human Genetics 102, 88–102, January 4,50% higher odds of suffering a fracture. Significant genetic
correlations with other traits (i.e., BMI, IGF1, and ulcerative
colitis) reflect the systemic context of skeletal biology and
merit further studyby future efforts to elucidate the underly-
ing mechanisms.
Genes in the associated loci were highly expressed in
the musculoskeletal system and overrepresented in gene
sets related to bone development. The prioritized gene
CREB3L1 (MIM: 616215) in 11p11.2 observed a clear
bone phenotype in ourmouse knockoutmodel, which cor-
roborates the findings of previous work showing substan-
tial rescue of CREB3L1 deficiency with bisphosphonates
and its critical role for bone formation.66 This locus,
characterized by extended LD, also harbors LRP4 (MIM:
604270) whose knockout model presents with increased
trabecular and cortical bone mass.67 This is in line with
our conditional analysis identifying multiple independent
signals in the region, making it likely that both genes are
influencing bone biology. Altogether, we demonstrated
that TB-BMD offers a powerful alternative to identify ge-
netic variants associated with bone metabolism.
Variants mapping to 14q32 harboring RIN3 (MIM:
610223) were associated only at a GWS level in children
(i.e., <15 years) and were only nominally significant in
the elderly group (i.e., >60 years). This age-related hetero-
geneity may explain why this locus has not been detected
in BMDmeta-analyses in adults, although being identified
in relation to pediatric BMD7 and Paget disease (PDB [MIM:
602080]) GWASs.68 In addition, another signal mapping
to 19q12 harboring TSHZ3 (MIM: 614119) was significant
in adults aged 45–60 years but not in other age groups
analyzed or in previous studies, alluding to a false-positive
association, so replication of this finding is necessary.
Our analyses revealed variants in the 6q25.1 (ESR1) and
13q14.11 (RANKL) loci demonstrating themost compelling
evidence for age-modulation effects. The 6q25.1 locus
harboringESR1 (MIM:133430), an important genetic factor
in normal BMD variability, was not associated with BMD in
children below 15 years of age, where the largest cohorts
(i.e., Avon Longitudinal Study of Parents and Children
[ALSPAC] and the Generation R Study) comprise predomi-
nantly pre-pubertal children. As levels of estradiol before
puberty are low,69 a negligible effect of ESR1 variants on
BMD is expected. Likewise, inmousemodels the expression
of RANKL (MIM: 602642) in bone is markedly increased
with advancing age from young to adult and related to
bone loss.70 Accordingly, variants influencing RANKL
expression show a larger effect later in life. In general, a sub-
stantial heterogeneity of the genetic effects in the overall
meta-analysis was explained by age, but the inclusion of
larger sample sizes (avoiding age exclusion criteria and in-
crementing statistical power) leveled off the loss of power
due to the heterogeneity of the genetic effects.
In brief, variants with evidence of age-specific effects were
exceptional in our study. These resultsmight reflect a lack of
statistical power as only SNPs showing suggestive evidence
(p < 5 3 106) of association with TB-BMD in the overall2018
meta-analysis were tested for age-specific effects. This selec-
tion criteria aimed to include SNPs whose heterogeneity
might have hampered their statistical significance in the
overall meta-analysis, and at the same time maximize the
power to discover variants with real age-dependent effects.
Alternatively, these results indicate that most of the genetic
variants identified so far, by us and others, influence BMD
from early ages onward, and their effect persist throughout
the life course. However, variants in 27 of the 42 loci (64%)
showing nominal evidence for age-dependent effects had
larger effects in the older groups. Nonetheless, this requires
careful interpretation given the uneven sample sizes be-
tween the age groups and the criteria to select markers for
the meta-regression based on significance in the overall
meta-analysis. Collectively, this argues in favor of enlarging
studies focused on younger populations—where the statisti-
cal power is still restricted—to discover additional genetic
variants influencing BMD.
Our study has some limitations. A key disadvantage of
our design is that we group the data based on age spans
rather than life stages. Crucial information for this assess-
ment, such as puberty onset in children and adolescents
or menopausal status in the adults, was not available across
the majority of the cohorts. Other strategies like using
smaller age spans will result in even less statistical power
of the discovery setting. Similarly, despite the large sample
size of our study, we identified very few variants in the low-
frequency spectrum (MAF < 5%), indicating that compre-
hensive surveys of rare variation influencing BMD still
require even larger sample sizes, on top of better resources
for imputation of the rarer variants, possibly needing pop-
ulation-specific references. Such strategies will be key to
explain a larger fraction of the genetic variability of BMD
phenotypes, as illustrated for other traits such as height
or BMI.71 Moreover, the identified SNPs are, in the vast
majority, non-coding variants, raising the possibility that
the causal genes are different from the candidate genes
we have prioritized based on the current biological knowl-
edge and bioinformatic prediction tools. Additional func-
tional studies are required to determine the potential role
of the genes in the identified loci.
In conclusion, we performed a genome-wide survey for
association with DXA-derived TB-BMD, combining data
from five age groups including children and older individ-
uals. In contrast to previous large-scale meta-analyses,5,6
we used DXA-derived TB-BMD rather than measurements
on specific skeletal sites prone to fracture to identify ge-
netic factors influencing BMD variation. We demonstrate
that TB-BMD is a valid phenotype for this purpose, as we
replicated more than 90% of the previously reported sig-
nals. Most importantly, we identify variants in 36 loci asso-
ciated with TB-BMD not previously reported by previous
GWASs of bone phenotypes. Our results show steadiness
in the magnitude of the genetic effects on BMD for most
of the BMD-associated variants. While the contrasting
skeletal physiology across different age periods is well
established (i.e., endochondral ossification, linear growth,The Amemodeling, remodeling, etc.), peak bone mass acquisition
remains the major determinant of variability at any age.
These findings strongly support the importance of the
bone accrual process in the definition of BMD status and
fracture susceptibility throughout the life course.Accession Numbers
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